INTI.US Inhibitor Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0800 USD
Close of Nov 15, 2026
0.0400 0.1240
Market cap
USD 14.0M
P/E
-
P/B
9.89x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is INTI.US undervalued?

Graham number

The Graham number of Inhibitor Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inhibitor Therapeutics Inc fundamental analysis

No fundamental analysis for Inhibitor Therapeutics Inc yet.

Inhibitor Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inhibitor Therapeutics Inc

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcino…

Full company profile